BR9507716A - Processo para suprimir expressão de vcam-1 processo para suprimir expressão de gene sensivel a redox processo para ativar gene progesso previsão ou avaliação de doenças mediadas pro vcma- 1 em vivo processo para previsão de avaliação de doença mediada por gene sensivel a redor in vivo processo para avaliação de sensibilidade de células endoteliais vasculares processo para selecionar compostos processo para tratamento de doença cardiovascular processo para supressão de expressão de vcam-1 em células humanas processo para tratamento de doença de pele inflamatória processo para tratamento de doença endotelial humana processo para tratamento de condição inflamatoria e composição farmacéutica - Google Patents
Processo para suprimir expressão de vcam-1 processo para suprimir expressão de gene sensivel a redox processo para ativar gene progesso previsão ou avaliação de doenças mediadas pro vcma- 1 em vivo processo para previsão de avaliação de doença mediada por gene sensivel a redor in vivo processo para avaliação de sensibilidade de células endoteliais vasculares processo para selecionar compostos processo para tratamento de doença cardiovascular processo para supressão de expressão de vcam-1 em células humanas processo para tratamento de doença de pele inflamatória processo para tratamento de doença endotelial humana processo para tratamento de condição inflamatoria e composição farmacéuticaInfo
- Publication number
- BR9507716A BR9507716A BR9507716A BR9507716A BR9507716A BR 9507716 A BR9507716 A BR 9507716A BR 9507716 A BR9507716 A BR 9507716A BR 9507716 A BR9507716 A BR 9507716A BR 9507716 A BR9507716 A BR 9507716A
- Authority
- BR
- Brazil
- Prior art keywords
- treating
- evaluation
- disease
- suppressing expression
- vcam
- Prior art date
Links
- 238000000034 method Methods 0.000 title 11
- 201000010099 disease Diseases 0.000 title 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 3
- 238000011156 evaluation Methods 0.000 title 3
- 108090000623 proteins and genes Proteins 0.000 title 3
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 title 2
- 238000001727 in vivo Methods 0.000 title 2
- 230000001404 mediated effect Effects 0.000 title 2
- 208000024172 Cardiovascular disease Diseases 0.000 title 1
- 201000004624 Dermatitis Diseases 0.000 title 1
- 230000003213 activating effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000003511 endothelial effect Effects 0.000 title 1
- 210000005260 human cell Anatomy 0.000 title 1
- 230000002757 inflammatory effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000035945 sensitivity Effects 0.000 title 1
- 210000003556 vascular endothelial cell Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/21—Radicals derived from sulfur analogues of carbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C333/02—Monothiocarbamic acids; Derivatives thereof
- C07C333/04—Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C333/02—Monothiocarbamic acids; Derivatives thereof
- C07C333/08—Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C333/14—Dithiocarbamic acids; Derivatives thereof
- C07C333/16—Salts of dithiocarbamic acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/323—Arteriosclerosis, Stenosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/20—Oxygen containing
- Y10T436/200833—Carbonyl, ether, aldehyde or ketone containing
- Y10T436/201666—Carboxylic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24085894A | 1994-05-10 | 1994-05-10 | |
US08/317,399 US5807884A (en) | 1992-10-30 | 1994-10-04 | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
PCT/US1995/005880 WO1995030415A1 (en) | 1994-05-10 | 1995-05-10 | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9507716A true BR9507716A (pt) | 1997-09-23 |
Family
ID=26933783
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9507716A BR9507716A (pt) | 1994-05-10 | 1995-05-10 | Processo para suprimir expressão de vcam-1 processo para suprimir expressão de gene sensivel a redox processo para ativar gene progesso previsão ou avaliação de doenças mediadas pro vcma- 1 em vivo processo para previsão de avaliação de doença mediada por gene sensivel a redor in vivo processo para avaliação de sensibilidade de células endoteliais vasculares processo para selecionar compostos processo para tratamento de doença cardiovascular processo para supressão de expressão de vcam-1 em células humanas processo para tratamento de doença de pele inflamatória processo para tratamento de doença endotelial humana processo para tratamento de condição inflamatoria e composição farmacéutica |
Country Status (17)
Country | Link |
---|---|
US (6) | US5807884A (pt) |
EP (1) | EP0759752A4 (pt) |
JP (1) | JP3120091B2 (pt) |
KR (1) | KR100394157B1 (pt) |
CN (1) | CN1152869A (pt) |
BG (1) | BG101030A (pt) |
BR (1) | BR9507716A (pt) |
CA (1) | CA2189336A1 (pt) |
CZ (1) | CZ330896A3 (pt) |
GE (1) | GEP20012409B (pt) |
HU (1) | HUT76728A (pt) |
MX (1) | MX9605450A (pt) |
NO (1) | NO964742L (pt) |
NZ (1) | NZ287214A (pt) |
PL (2) | PL180874B1 (pt) |
SK (1) | SK136496A3 (pt) |
WO (1) | WO1995030415A1 (pt) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5783596A (en) * | 1992-10-30 | 1998-07-21 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
US5380747A (en) * | 1992-10-30 | 1995-01-10 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
US5807884A (en) * | 1992-10-30 | 1998-09-15 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
AUPM906594A0 (en) * | 1994-10-26 | 1994-11-17 | Peptide Technology Limited | Synthetic polyunsaturated fatty acid analogues |
US5571523A (en) * | 1995-03-09 | 1996-11-05 | President And Fellows Of Harvard College | Antioxidant-induced apoptosis in vascular smooth muscle cells |
US5741815A (en) * | 1995-06-02 | 1998-04-21 | Lai; Ching-San | Methods for in vivo reduction of nitric oxide levels and compositions useful therefor |
US5792787A (en) * | 1995-06-07 | 1998-08-11 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
CA2237191A1 (en) * | 1996-09-20 | 1998-03-26 | Atherogenics, Inc. | Diagnostics for and mediators of inflammatory disorders |
AU731937B2 (en) * | 1996-12-10 | 2001-04-05 | Hadasit Medical Research Services & Development Company Ltd | Serum-derived factor inducing cell differentiation and medical uses thereof |
GB2321455A (en) | 1997-01-24 | 1998-07-29 | Norsk Hydro As | Lipophilic derivatives of biologically active compounds |
EP1695959A1 (en) * | 1997-05-14 | 2006-08-30 | Atherogenics, Inc. | Compouds and methods for the inhibition of the expression of VCAM-1 |
US6670398B2 (en) * | 1997-05-14 | 2003-12-30 | Atherogenics, Inc. | Compounds and methods for treating transplant rejection |
NZ528906A (en) | 1997-05-14 | 2005-06-24 | Atherogenics Inc | Compounds and methods for the inhibition of the expression of VCAM-1 |
US6852878B2 (en) | 1998-05-14 | 2005-02-08 | Atherogenics, Inc. | Thioketals and thioethers for inhibiting the expression of VCAM-1 |
CN1261803A (zh) * | 1997-07-01 | 2000-08-02 | 埃瑟若詹尼克斯公司 | 抗氧化剂增强对细胞过度增生性疾病的治疗 |
US6989435B2 (en) | 1997-09-11 | 2006-01-24 | Cambridge University Technical Services Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
US7067117B1 (en) | 1997-09-11 | 2006-06-27 | Cambridge University Technical Services, Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
US6761888B1 (en) * | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
IL122892A0 (en) | 1998-01-11 | 1998-08-16 | Yeda Res & Dev | Pharmaceutical compositions comprising a thiocarbamate |
IL122891A0 (en) | 1998-01-11 | 1998-08-16 | Yeda Res & Dev | Pharmaceutical compositions comprising a thiocarbamate |
CA2658200A1 (en) * | 1998-07-06 | 2000-01-13 | Mgi Gp, Inc. | Naaladase inhibitors useful as pharmaceutical compounds and compositions |
ES2251204T3 (es) * | 1998-07-06 | 2006-04-16 | Mgi Gp, Inc. | Inhibidores de naaladasa utiles como compuestos y composiciones farmaceuticas. |
US6706759B1 (en) | 1998-09-08 | 2004-03-16 | Charlotte-Mecklenburg Hospital Authority | Method of treating cancer using dithiocarbamate derivatives |
US6548540B2 (en) * | 1998-09-08 | 2003-04-15 | Charlotte-Mecklenburg Hospital Authority | Method of treating cancer using dithiocarbamate derivatives |
US7816403B2 (en) | 1998-09-08 | 2010-10-19 | University Of Utah Research Foundation | Method of inhibiting ATF/CREB and cancer cell growth and pharmaceutical compositions for same |
US6589987B2 (en) | 1998-09-08 | 2003-07-08 | Charlotte-Mecklenburg Hospital Authority | Method of treating cancer using tetraethyl thiuram disulfide |
US20050197283A1 (en) * | 1998-10-04 | 2005-09-08 | Vascular Biogenics Ltd. | Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of vascular disease |
IL126447A (en) * | 1998-10-04 | 2004-09-27 | Vascular Biogenics Ltd | An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis |
US6887712B1 (en) | 1998-11-09 | 2005-05-03 | Atherogenics, Inc. | Methods and compositions to lower plasma cholesterol levels |
US6372187B1 (en) | 1998-12-07 | 2002-04-16 | Mcdermott Technology, Inc. | Alkaline sorbent injection for mercury control |
US7238711B1 (en) | 1999-03-17 | 2007-07-03 | Cambridge University Technical Services Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
WO2000046183A1 (en) | 1999-02-08 | 2000-08-10 | Checkpoint Genetics, Inc. | N-substituted amino acids, antioxidant pharmaceutical compositions containing same and methods using same |
US6284199B1 (en) * | 1999-03-31 | 2001-09-04 | Mcdermott Technology, Inc. | Apparatus for control of mercury |
US6855859B2 (en) * | 1999-03-31 | 2005-02-15 | The Babcock & Wilcox Company | Method for controlling elemental mercury emissions |
US6734192B1 (en) | 1999-08-23 | 2004-05-11 | Mp-1 Inc. | Treatment of viral infections |
US6710086B1 (en) | 2000-02-25 | 2004-03-23 | Medinox, Inc. | Protected forms of pharmacologically active agents and uses therefor |
AU2001247649A1 (en) | 2000-03-21 | 2001-10-30 | Atherogenics, Inc | N-substituted dithiocarbamates for the treatment of biological disorders |
JP2003530383A (ja) | 2000-04-11 | 2003-10-14 | アセロジエニクス・インコーポレイテツド | 血漿hdlコレステロールレベルを上昇させ、hdl機能性を向上させる化合物および方法 |
IL151348A0 (en) | 2000-04-13 | 2003-04-10 | Univ Rockefeller | Enhancement of antibody-mediated immune responses |
AU2001296959A1 (en) * | 2000-10-02 | 2002-04-15 | Reddy Us Therapeutics, Inc | Methods and compositions for the treatment of inflammatory diseases |
CA2428753C (en) | 2000-11-17 | 2013-05-21 | Idenix (Cayman) Limited | Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines |
CA2429817C (en) | 2000-11-24 | 2013-02-12 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
NO20006008L (no) * | 2000-11-28 | 2002-05-29 | Thia Medica As | Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer |
IL156651A0 (en) * | 2000-12-29 | 2004-01-04 | Reddy Us Therapeutics Inc | Detection of compounds that modulate inflammatory responses |
US7223552B2 (en) | 2001-01-02 | 2007-05-29 | The Cleveland Clinic Foundation | Myeloperoxidase, a risk indicator for cardiovascular disease |
US6596708B1 (en) | 2001-09-07 | 2003-07-22 | Advanced Medical Instruments | Composition for the treatment and prevention of endothelial dysfunction |
US20040157280A1 (en) * | 2001-09-17 | 2004-08-12 | Paul Wentworth | Antibody mediated ozone generation |
US20050129680A1 (en) * | 2001-09-17 | 2005-06-16 | Paul Wentworth | Antimicrobial activity of antibodies |
US20040116350A1 (en) * | 2001-09-17 | 2004-06-17 | Paul Wentworth Jr | Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies |
HUP0500165A2 (en) | 2001-12-19 | 2006-09-28 | Atherogenics Inc | Chalcone derivatives and their use to treat diseases |
US20030147958A1 (en) * | 2002-01-29 | 2003-08-07 | Cheol-Hee Ahn | Biodegradable multi-block copolymers of poly(amino acid)s and poly(ethylene glycol) for the delivery of bioactive agents |
WO2004044582A2 (en) * | 2002-11-14 | 2004-05-27 | Novartis Ag | Antibody- or neutrophil-mediated ozone generation |
US8017651B2 (en) * | 2002-11-22 | 2011-09-13 | Bionexus, Ltd. | Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia |
AU2003303239A1 (en) * | 2002-12-19 | 2004-07-14 | Atherogenics, Inc. | Process of making chalcone derivatives |
WO2004104022A2 (en) * | 2003-05-16 | 2004-12-02 | The General Hospital Corporation | Compositions comprising pathogen elicited epithelial chemoattractant (eicosanoid hepoxilin a3), inhibitors thereof and methods of use thereof |
WO2004108094A2 (en) * | 2003-06-06 | 2004-12-16 | Atherogenics, Inc. | Sulfonamide-substituted chalcone derivatives and their use to treat diseases |
US20060025481A1 (en) * | 2004-02-09 | 2006-02-02 | Strange Matthew L | Process for preparation of probucol derivatives and polymorphic forms thereof |
US7294736B2 (en) * | 2004-04-09 | 2007-11-13 | Cambrex Charles City, Inc. | Process for preparation of probucol derivatives |
WO2005112914A2 (en) | 2004-04-20 | 2005-12-01 | Atherogenics, Inc. | Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease |
US20060063828A1 (en) * | 2004-06-28 | 2006-03-23 | Weingarten M D | 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof |
EP1812793A4 (en) * | 2004-11-15 | 2008-04-16 | Quantomix Ltd | DEVICE AND METHOD FOR ANALYZING A METAL CHANGING |
US7345191B2 (en) * | 2005-02-26 | 2008-03-18 | Cambrex Charles City, Inc. | Process for preparation of probucol derivatives |
US8071545B2 (en) * | 2005-03-15 | 2011-12-06 | Lewis S. Coleman, Md, Inc. | Therapies and compositions for controlling the stress mechanism and for stabilizing hemostasis in an organism |
US7767710B2 (en) | 2005-05-25 | 2010-08-03 | Calosyn Pharma, Inc. | Method for treating osteoarthritis |
US20060269579A1 (en) * | 2005-05-25 | 2006-11-30 | Musculoskeletal Research Llc | Compositions for treating osteoarthritis |
KR100823533B1 (ko) | 2007-02-27 | 2008-04-30 | 바이오스펙트럼 주식회사 | 알파 비사볼올을 유효성분으로 포함하는 피부 상태 개선용조성물 |
BRPI0809423A2 (pt) * | 2007-03-26 | 2014-09-09 | Salutria Pharmaceuticals Llc | Usos e composições de derivados de probucol para o tratamento de diabetes |
US20080280985A1 (en) * | 2007-03-27 | 2008-11-13 | Scott Robert A D | Methods and Compositions Using Certain Phenolic Derivatives for the Treatment of Diabetes |
WO2009042854A1 (en) * | 2007-09-26 | 2009-04-02 | Musculoskeletal Research Llc | Ion-channel regulator compositions and methods of using same |
CA2744819A1 (en) * | 2008-11-26 | 2010-06-03 | Amol Madhusudan Patwardhan | Combination of ketoconazole and nordihydroguaiaretic acid, and uses thereof for example in the treatment of pain associated with burns |
CN102250045A (zh) * | 2010-05-21 | 2011-11-23 | 复旦大学附属华山医院 | 抗结核分支杆菌的化合物及其应用 |
WO2012040656A2 (en) * | 2010-09-24 | 2012-03-29 | Sciclone Pharmaceuticals, Inc. | Biomarkers to track response to scv-07 |
US9029342B2 (en) | 2012-09-17 | 2015-05-12 | Board Of Regents Of The University Of Texas System | Compositions of matter that reduce pain, shock, and inflammation by blocking linoleic acid metabolites and uses thereof |
KR101834469B1 (ko) * | 2013-08-07 | 2018-03-06 | 알렉시온 파마슈티칼스, 인코포레이티드 | 비정형적 용혈성 요독증후군 (ahus) 바이오마커 단백질 |
WO2015071766A1 (en) * | 2013-11-15 | 2015-05-21 | Dignity Sciences Limited | Pharmaceutically acceptable salts of polyunsaturated hydroxy fatty acids |
US10905062B2 (en) * | 2015-10-19 | 2021-02-02 | General Mills, Inc. | High protein oat species |
RU2662316C1 (ru) * | 2017-08-31 | 2018-07-25 | Сергей Владимирович Кунгурцев | Жидкофазная композиция с повышенным содержанием природных устойчивых к окислению омега-3 полинепредельных жирных кислот |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3875170A (en) * | 1971-05-25 | 1975-04-01 | Banyu Pharma Co Ltd | Pyridine bis (dithiocarbamate) derivatives |
US4025527A (en) * | 1973-07-13 | 1977-05-24 | Smith Kline & French Laboratories Limited | Certain thiazoles and oxazoles |
GB1542840A (en) * | 1975-02-03 | 1979-03-28 | Smith Kline French Lab | Heterocyclic dithiocarbamates and isothioureas |
US4670471A (en) * | 1981-11-03 | 1987-06-02 | Clark Lealand L | Treatment for inflammatory skin disease |
US4522811A (en) * | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
GB8421039D0 (en) * | 1984-08-17 | 1984-09-19 | Wyeth John & Brother Ltd | Heterocyclic compounds |
ATE68013T1 (de) * | 1985-07-05 | 1991-10-15 | Whitehead Biomedical Inst | Expression von fremdem genetischem material in epithelzellen. |
US4980286A (en) * | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
EP0284879A3 (en) * | 1987-03-17 | 1990-10-17 | Merrell Dow Pharmaceuticals Inc. | Method of inhibiting interleukin-1 release |
US4870101A (en) * | 1987-03-17 | 1989-09-26 | Merrell Dow Pharmaceuticals Inc. | Method of inhibiting interleukin-1 release |
US5035878A (en) * | 1988-09-12 | 1991-07-30 | University Of Rochester | Use of dithiocarbamates to counteract myelosuppression |
US5166133A (en) * | 1991-04-17 | 1992-11-24 | Cetus Corporation | Method for inhibing adhesion of white blood cells to endothelial cells |
WO1993001286A2 (en) * | 1991-06-28 | 1993-01-21 | Massachusetts Institute Of Technology | Localized oligonucleotide therapy |
FR2679452B1 (fr) * | 1991-07-22 | 1993-11-12 | Cis Bio International | Produit radiopharmaceutique ayant notamment un tropisme cerebral, comportant un complexe nitruro d'un metal de transition, et son procede de preparation. |
US5206264A (en) * | 1991-11-04 | 1993-04-27 | Cypros Pharmaceutical Corporation | Use of disulfiram to prevent cardiovascular damage |
US5306724A (en) * | 1992-08-17 | 1994-04-26 | Clintec Nutrition Company | Method for preventing and treating atherosclerosis |
US5380747A (en) * | 1992-10-30 | 1995-01-10 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
US5807884A (en) * | 1992-10-30 | 1998-09-15 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
US5792787A (en) * | 1995-06-07 | 1998-08-11 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
-
1994
- 1994-10-04 US US08/317,399 patent/US5807884A/en not_active Expired - Lifetime
-
1995
- 1995-05-10 MX MX9605450A patent/MX9605450A/es unknown
- 1995-05-10 PL PL95317193A patent/PL180874B1/pl not_active IP Right Cessation
- 1995-05-10 BR BR9507716A patent/BR9507716A/pt not_active Application Discontinuation
- 1995-05-10 WO PCT/US1995/005880 patent/WO1995030415A1/en not_active Application Discontinuation
- 1995-05-10 NZ NZ287214A patent/NZ287214A/en not_active IP Right Cessation
- 1995-05-10 SK SK1364-96A patent/SK136496A3/sk unknown
- 1995-05-10 GE GEAP19953488A patent/GEP20012409B/en unknown
- 1995-05-10 CA CA002189336A patent/CA2189336A1/en not_active Abandoned
- 1995-05-10 PL PL95342067A patent/PL184466B1/pl not_active IP Right Cessation
- 1995-05-10 HU HU9603041A patent/HUT76728A/hu unknown
- 1995-05-10 KR KR1019960706348A patent/KR100394157B1/ko not_active IP Right Cessation
- 1995-05-10 CN CN95194077A patent/CN1152869A/zh active Pending
- 1995-05-10 EP EP95920396A patent/EP0759752A4/en not_active Withdrawn
- 1995-05-10 CZ CZ963308A patent/CZ330896A3/cs unknown
- 1995-05-10 JP JP07529200A patent/JP3120091B2/ja not_active Expired - Fee Related
- 1995-06-06 US US08/471,537 patent/US5846959A/en not_active Expired - Lifetime
- 1995-06-07 US US08/484,059 patent/US5773209A/en not_active Expired - Lifetime
- 1995-06-07 US US08/474,530 patent/US5750351A/en not_active Expired - Lifetime
- 1995-06-07 US US08/483,335 patent/US5811449A/en not_active Expired - Lifetime
- 1995-06-07 US US08/473,272 patent/US5773231A/en not_active Expired - Lifetime
-
1996
- 1996-11-08 NO NO964742A patent/NO964742L/no not_active Application Discontinuation
- 1996-12-05 BG BG101030A patent/BG101030A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
WO1995030415A1 (en) | 1995-11-16 |
US5773209A (en) | 1998-06-30 |
EP0759752A4 (en) | 2001-08-08 |
NO964742D0 (no) | 1996-11-08 |
CA2189336A1 (en) | 1995-11-16 |
US5811449A (en) | 1998-09-22 |
JP3120091B2 (ja) | 2000-12-25 |
US5750351A (en) | 1998-05-12 |
PL180874B1 (pl) | 2001-04-30 |
HUT76728A (en) | 1997-11-28 |
MX9605450A (es) | 1997-12-31 |
US5807884A (en) | 1998-09-15 |
GEP20012409B (en) | 2001-04-25 |
PL184466B1 (pl) | 2002-11-29 |
SK136496A3 (en) | 1999-01-11 |
BG101030A (en) | 1997-09-30 |
KR100394157B1 (ko) | 2004-02-11 |
US5773231A (en) | 1998-06-30 |
US5846959A (en) | 1998-12-08 |
NO964742L (no) | 1996-11-08 |
EP0759752A1 (en) | 1997-03-05 |
CZ330896A3 (cs) | 1998-07-15 |
HU9603041D0 (en) | 1997-01-28 |
JPH10500111A (ja) | 1998-01-06 |
NZ287214A (en) | 2001-05-25 |
CN1152869A (zh) | 1997-06-25 |
PL317193A1 (en) | 1997-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9507716A (pt) | Processo para suprimir expressão de vcam-1 processo para suprimir expressão de gene sensivel a redox processo para ativar gene progesso previsão ou avaliação de doenças mediadas pro vcma- 1 em vivo processo para previsão de avaliação de doença mediada por gene sensivel a redor in vivo processo para avaliação de sensibilidade de células endoteliais vasculares processo para selecionar compostos processo para tratamento de doença cardiovascular processo para supressão de expressão de vcam-1 em células humanas processo para tratamento de doença de pele inflamatória processo para tratamento de doença endotelial humana processo para tratamento de condição inflamatoria e composição farmacéutica | |
Fluhr et al. | Bioengineering of the skin: water and the stratum corneum | |
Wilmink et al. | Differences in second‐intention wound healing between horses and ponies: macroscopic aspects | |
Valacchi et al. | Ozone exposure activates oxidative stress responses in murine skin | |
Sehn et al. | Dynamics of reepithelialisation and penetration rate of a bee propolis formulation during cutaneous wounds healing | |
Degim | New tools and approaches for predicting skin permeability | |
Kikuchi et al. | Improvement of Mild Inflammatory Changes of the Facial Skin Induced by Winter Environment with Daily Applications of a Moisturizing CreamA Half-Side Test of Biophysical Skin Parameters, Cytokine Expression Pattern and the Formation of Cornified Envelope | |
Lademann et al. | Follicular penetration and targeting | |
BR9508417A (pt) | Acido nucléico isolado cdna isolado proteina isolada vetor de expressão processo para detectar câncer e pré-câncer de pulmão processo para selecionar especimes humanas para proteina hcaviii processo para testar amostra de célula humana anticorpo e composição terapêutica | |
BR9800660A (pt) | Emulsão água-em-óleo sua utilização composição cosmética e/ou dermatológica processo de tratamento cosmético e utilzação de uma associação | |
JP5978319B2 (ja) | オオスズメバチ毒抽出方法およびこれを利用した機能性化粧料組成物 | |
BR8008073A (pt) | Processo para deteccao de sangue oculto em especimes humanos e processo para deteccao quantitativa da presenca de sangue oculto em materia fecal | |
Held et al. | Comparison between 2 test models in evaluating the effect of a moisturizer on irritated human skin | |
Joerring et al. | Types I and III procollagen extension peptides in serum respond to fracture in humans | |
Lodén | Do moisturizers work? | |
Butko et al. | Immune histochemical study of KI-67 level and ribonucleic acid in the process of healing of burn wounds after treatment with drugs containing dexpanthenol and ceramide | |
JP2012189581A (ja) | 皮膚のストレス蓄積度の評価方法 | |
Wang et al. | Oxidative modifications of LDL increase its binding to extracellular matrix from human aortic intima: influence of lesion development, lipoprotein lipase and calcium | |
BR0302158A (pt) | Processo e kit para medir a inflamação ou a irritação da pele | |
TWI600904B (zh) | 皮膚應激蓄積度的評價方法 | |
Yang et al. | A computational model of fibroblast and macrophage spatial/temporal dynamics in foreign body reactions | |
Sambuco et al. | Quantitative assessment of phototoxicity in the skin of hairless mice | |
Lansdown | An appraisal of methods for detecting primary skin irritants | |
Vega-Lopez et al. | Sex and hormonal status modulate the effects of psyllium on plasma lipids and monocyte gene expression in humans | |
Domínguez-Delgado et al. | The skin a valuable route for administration of drugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |